Seviteronel
Estrogen-Receptor Positive Breast Cancer
Explore 74 assets in Estrogen-Receptor Positive Breast Cancer →Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Innocrin Pharmaceutical
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02580448CT.gov CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Estrogen-Receptor Positive Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Seviteronel (this asset) | Innocrin Pharmaceutical | P1/2 | CCC · 50 |
| Exemestane | National Cancer Institute (NCI) | P4 | BBB |
| Tamoxifen | Dana-Farber Cancer Institute | P4 | BB |
| Everolimus | UNC Lineberger Comprehensive Cancer Center | P4 | BB |
| Abemaciclib | Jonsson Comprehensive Cancer Center | P3 | BB |
| Giredestrant | Hoffmann-La Roche | P3 | BB |
| Palbociclib | Forward Pharmaceuticals Co., Ltd. | P3 | BB |
| Cyclophosphamide | UNC Lineberger Comprehensive Cancer Center | P2 | BB |
| Elacestrant | Kristina A. Fanucci | P3 | BB |
+42 more in the Estrogen-Receptor Positive Breast Cancer cohort
Other indications for Seviteronel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Castration-Resistant Prostate Carcinoma | — | P2 | B · 61 |
| Breast Cancer | — | P1/2 | CCC · 52 |
| Prostate Cancer | — | P2 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Seviteronel in Estrogen-Receptor Positive Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/seviteronel-estrogen-receptor-positive-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →